Pacific Bio (PACB) Tops Q4 EPS by 3c

Pacific Bio (NASDAQ: PACB) reported Q4 EPS of ($0.12), $0.03 better than the analyst estimate of ($0.15). Revenue for the quarter came in at $44.6 million versus the consensus estimate of $42.27 million.

For earnings history and earnings-related data on Pacific Bio (PACB) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• AMD (AMD) PT Raised to $670 at UBS on Higher Share Expectations
• Phio Pharmaceuticals begins commercial-scale production of PH-762